- 17Volume 4, 2021May 04, Issue 9Apr 20, Issue 8Apr 06, Issue 7Mar 23, Issue 6Mar 09, Issue 5Feb 23, Issue 4Feb 09, Issue 3Jan 26, Issue 2
- 16Volume 3, 2020Dec 15, Issue 25Dec 01, Issue 24Nov 17, Issue 23Oct 06, Issue 20Sep 08, Issue 18Aug 25, Issue 17Jul 14, Issue 14Jun 30, Issue 13Jun 16, Issue 12Jun 02, Issue 11May 19, Issue 10May 05, Issue 9Mar 10, Issue 5Feb 25, Issue 4Feb 04, Issue 3Jan 21, Issue 2Jan 07, Issue 01
- 15Volume 2, 2019Dec 17, Issue 22Nov 12, Issue 20Oct 28, Issue 19Oct 15, Issue 18Sep 03, Issue 15Aug 21, Issue 14Aug 05, Issue 13Jul 22, Issue 12Jul 08, Issue 11Jun 03, Issue 9May 13, Issue 8Apr 22, Issue 7Mar 11, Issue 4Feb 04, Issue 2Jan 21, Issue 1
- 14Volume 1, 2018Dec 21, Issue 12Dec 03, Issue 11Nov 19, Issue 10Nov 05, Issue 9Oct 22, Issue 8Oct 09, Issue 7Sep 24, Issue 6Sep 10, Issue 5Aug 15, Issue 4Jul 15, Issue 3Jul 01, Issue 1
Agenus on Twitter
Agenus Corporate Update and First Quarter 2021 Financial Report •Balstilimab BLA submitted to FDA for recurrent/metastatic cervical cancer •Balstilimab and AGEN2373 data to be presented at ASCO •iNKT cell therapy Phase 1 initiated in cancer investor.agenusbio.com/news-releases/…
Agenus' CMO Dr. Steven O’Day spoke today at the World Vaccine Congress about ‘Future Perspectives for Combination Immunotherapies’ Today's newsletter The Agenus Difference discusses the importance of combinations & our continued innovation w this approach agenusbio.com/newsletters/ag…
TUNE IN! Panel on Future Perspectives for Combination Immunotherapies starts at 1pm ET! Hear Dr. Steven O'Day at the World Vaccine Congress 2021: terrapinn.com/conference/wor… @ODayMD @vaccinenation #WVCUSA #Immunotherapy #CancerResearch
Hear $AGEN CMO Dr. Steven O'Day's thoughts on the promises and challenges of combination immunotherapies at the World Vaccine Congress 2021 TODAY at 1pm! Click to register and watch: terrapinn.com/conference/wor… @ODayMD @vaccinenation #WVCUSA
Agenus to Present at the 2021 ASCO Annual Meeting Agenus will present on two of its programs, balstilimab (anti-PD-1) and AGEN2373 (CD137 agonist antibody) @ASCO #ASCO21 #oncology #immunotherapy investor.agenusbio.com/news-releases/…
Agenus' CMO Dr. Steven O'Day will be at the World Vaccine Congress Washington 2021! Mark your calendars for the panel on Future Perspectives for Combination Immunotherapies on May 4. Click for more information & to register: terrapinn.com/conference/wor… @ODayMD @vaccinenation #WVCUSA
"FDA Approval Sought for Balstilimab for Recurrent or Metastatic Cervical Cancer" Click to read @OncLive coverage of $AGEN submission of balstilimab (anti-PD-1) BLA for recurrent or metastatic #cervicalcancer. #immunotherapy #oncology onclive.com/view/fda-appro…
$AGEN latest newsletter now available: Agenus’ Own Unique Anti-CTLA-4 and Anti-PD-1 Antibodies Two presentations on AGEN1181 at #AACR21 showed that it appears to be working even in tumors that are not expected to respond to #immunotherapy. Read more: agenusbio.com/newsletters/v4…
Agenus Submits Balstilimab Biologics License Application to the U.S. FDA for Patients with Recurrent or Metastatic Cervical Cancer investor.agenusbio.com/news-releases/…
Agenus expects this therapy to be effective in both liquid and solid tumors based on preclinical models and to be potentially more affordable and more accessible than currently approved cell therapies. Click to learn more: boston.cbslocal.com/2021/04/14/age…
Agenus subsidiary @Agentus_CellTX dosed the first cancer patient with its iNKT #celltherapy! Watch Dr. @JoeGrossman7 discuss this immunotherapy and its potential to treat both #cancer and #COVID19.
Agenus Doses First Cancer Patient with iNKT Cell Therapy investor.agenusbio.com/news-releases/… The Phase 1 trial has been initiated in hematologic cancers @DanaFarber with expansion into solid tumors expected to begin shortly. Initial data readouts anticipated in 4Q2021 @Agentus_CellTX
Agenus' next-generation anti-CTLA-4 AGEN1181 is optimally designed with differentiated activity seen in the clinic. Watch $AGEN's CMO @ODayMD discuss the power of this cancer immunotherapy & the exciting responses presented at #AACR21! Click to learn more: investor.agenusbio.com/news-releases/…
New Clinical Responses for AGEN1181 Presented at #AACR21 investor.agenusbio.com/news-releases/…
Dr. @jbuell01, President & COO of $AGEN, will participate in the Precision Medicine in IO Panel at the 7th Annual Digital Immuno-Oncology Innovation Forum #sachs_IOIF #immunooncology #immunotherapy #precisionmedicine twitter.com/SachsAssociate…
Dr. Buell(@jbuell01) brings over 20 years of biopharmaceutical industry experience. Her efforts in the rapid advancement of discovery candidates through development has resulted in @Agenus_Bio' record of advancing numerous I-O candidates to the clinic in the past four years. pic.twitter.com/yObbEUhqPw
— Sachs Associates (@SachsAssociates) April 7, 2021
$AGEN senior management take bonus in equity over cash: investor.agenusbio.com/node/17711/html investor.agenusbio.com/node/17721/html
$AGEN latest newsletter now available: Optimally Targeting TIGIT TIGIT has emerged as the next validated I-O target w the potential to be a game-changing therapy for cancer patients. Click to read about the science of TIGIT & our bispecific AGEN1777: agenusbio.com/newsletters/v4…
Please to participate in #longwoodhealthcareleaders conference to discuss @Agenusbio #AI efforts & describe our #VISION Immune Platform to predict patient response twitter.com/LongwoodFund/s… Retweeted by Agenus Inc. ($AGEN)
Agenus @ #SGOMtg! @omalleygynonc presents on our RaPiDS trial, a collaboration w @GOG expected to further validate the use of bal+/-zal in 2L #cervicalcancer. Watch Dr. O'Malley discuss the trial & the potential to provide treatment to even more #patients agenusbio.com/newsletters/v4…
$AGEN latest newsletter now available: The Central Role of iNKT Cells: An Agenus Perspective This newsletter highlights the central role of iNKT cells in the immune system & their diverse functionality. Click to read more: agenusbio.com/newsletters/v4…